Skip to main content

Evenity Disease Interactions

There are 3 disease interactions with Evenity (romosozumab).


Romosozumab (applies to Evenity) hypocalcemia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Romosozumab is contraindicated in patients with hypocalcemia. Preexisting hypocalcemia must be corrected prior to initiating therapy. Monitor patients for signs and symptoms of hypocalcemia and adequately supplement them with calcium and vitamin D while on treatment. Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m2) or receiving dialysis are at greater risk of developing hypocalcemia and should be monitored closely. Instruct patients with severe renal impairment, including those receiving dialysis, about the symptoms of hypocalcemia and the importance of maintaining calcium levels with adequate calcium and vitamin D supplementation.


  1. "Product Information. Evenity (romosozumab)." Amgen USA (2019):

Romosozumab (applies to Evenity) myocardial infarction/stroke

Major Potential Hazard, Moderate plausibility. Applicable conditions: History - Myocardial Infarction, History - Cerebrovascular Disease, Cardiovascular Disease

Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death, and should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during therapy, romosozumab should be discontinued.


  1. "Product Information. Evenity (romosozumab)." Amgen USA (2019):

Romosozumab (applies to Evenity) osteonecrosis of the jaw

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Anemia, Coagulation Defect

Osteonecrosis of the jaw (ONJ), has been reported in patients receiving romosozumab. A routine oral examination should be performed prior to initiation of treatment. Risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, preexisting dental disease or infection, anemia, and coagulopathy, and concomitant use of other drugs associated with ONJ (e.g., chemotherapy, bisphosphonates). Patients requiring invasive dental procedures, require clinical judgment of the treating physician and/or oral surgeon to guide the management plan based on benefit-risk assessment. Patients who are suspected of having or who develop ONJ while on romosozumab treatment, should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of treatment should be considered based on benefit-risk assessment.


  1. "Product Information. Evenity (romosozumab)." Amgen USA (2019):

Evenity drug interactions

There are 40 drug interactions with Evenity (romosozumab).

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.